Warfarin traps human vitamin K epoxide reductase in an intermediate state during electron transfer
- Henan Univ. of Science and Technology, Luoyang (China). College of Medicine; Amgen Inc., Cambridge, MA (United States); Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics; OSTI
- Washington Univ., St. Louis, MO (United States). Dept. of Chemistry
- Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics
- Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics; Shanghai Jiao Tong Univ. (China). School of Chemistry and Chemical Engineering
- Washington Univ., St. Louis, MO (United States). School of Medicine and Dept. of Biochemistry and Molecular Biophysics; Huazhong Univ. of Science and Technology, Wuhan (China). Tongji Medical College and Dept. of Forensic Medicine
- Washington Univ., St. Louis, MO (United States). School of Medicine and Division of Hematology
Although warfarin is the most widely used anticoagulant worldwide, the mechanism by which warfarin inhibits its target, human vitamin K epoxide reductase (hVKOR), remains unclear. We show that warfarin blocks a dynamic electron-transfer process in hVKOR. A major fraction of cellular hVKOR is at an intermediate redox state of this process containing a Cys51-Cys132 disulfide, a characteristic accommodated by a four-transmembrane-helix structure of hVKOR. Warfarin selectively inhibits this major cellular form of hVKOR, whereas disruption of the Cys51-Cys132 disulfide impairs warfarin binding and causes warfarin resistance. Relying on binding interactions identified by cysteine alkylation footprinting and mass spectrometry coupled with mutagenesis analysis, we are able to conduct structure simulations to reveal a closed warfarin-binding pocket stabilized by the Cys51-Cys132 linkage. Understanding the selective warfarin inhibition of a specific redox state of hVKOR should enable the rational design of drugs that exploit the redox chemistry and associated conformational changes in hVKOR.
- Research Organization:
- Washington Univ., St. Louis, MO (United States)
- Sponsoring Organization:
- USDOE; China Scholarship Council (CSC); Burroughs Wellcome Fund (BWF); National Inst. of Health (NIH); American Heart Association (AHA); American Society of Hematology (ASH)
- Contributing Organization:
- Univ. of North Carolina, Chapel Hill, NC (United States); Umeå Univ. (Sweden)
- Grant/Contract Number:
- SC0001035
- OSTI ID:
- 1463095
- Journal Information:
- Nature Structural & Molecular Biology, Journal Name: Nature Structural & Molecular Biology Journal Issue: 1 Vol. 24; ISSN 1545-9993
- Publisher:
- Nature Publishing GroupCopyright Statement
- Country of Publication:
- United States
- Language:
- English
| Genetic variation in human drug-related genes | posted_content | June 2017 |
Structural Insights into Phylloquinone (Vitamin K1), Menaquinone (MK4, MK7), and Menadione (Vitamin K3) Binding to VKORC1
|
journal | January 2019 |
Warfarin and vitamin K epoxide reductase: a molecular accounting for observed inhibition
|
journal | August 2018 |
Genetic variation in human drug-related genes
|
journal | December 2017 |
Similar Records
Structural basis of antagonizing the vitamin K catalytic cycle for anticoagulation
Hepatic uptake and storage of warfarin. The relation with the target enzyme vitamin K 2,3-epoxide reductase